Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile
The submissions are supported by data from the Phase 3 KEYNOTE-905 trial
The expansion underscores Merck’s commitment to invest more than $70 billion in U.S. research, development and capital projects
Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutions
These findings follow positive Phase 3 results presented earlier this year
Merck will showcase results in innovative solutions in HIV treatment and prevention
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
Through this acquisition Merck has added Ohtuvayre (ensifentrine) to its growing cardio-pulmonary pipeline and portfolio
Merck and Siemens signed new MoU extending their strategic partnership to accelerate digital transformation in the life science industry
Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute
Subscribe To Our Newsletter & Stay Updated
